Market closedNon-fractional
Astria Therapeutics/ATXS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Astria Therapeutics
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Ticker
ATXS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
59
Website
www.astriatx.com
ATXS Metrics
BasicAdvanced
$656M
Market cap
-
P/E ratio
-$2.25
EPS
0.81
Beta
-
Dividend rate
Price and volume
Market cap
$656M
Beta
0.81
Financial strength
Current ratio
33.826
Quick ratio
33.409
Total debt to equity
0.046
Management effectiveness
Return on assets (TTM)
-16.43%
Return on equity (TTM)
-28.19%
Valuation
Price to book
2.4
Price to tangible book (TTM)
2.4
Price to free cash flow (TTM)
-5.823
Growth
Earnings per share change (TTM)
-13.26%
3-year earnings per share growth (CAGR)
-66.49%
What the Analysts think about ATXS
Analyst Ratings
Majority rating from 7 analysts.
ATXS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$20M
-36.62%
Profit margin
0.00%
NaN%
ATXS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.45
-$0.63
-$0.94
-$0.38
-
Expected
-$0.49
-$0.49
-$0.78
-$0.36
-$0.39
Surprise
-7.63%
29.63%
20.49%
4.40%
-
ATXS News
AllArticlesVideos
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
Business Wire·2 months ago
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Astria Therapeutics stock?
Astria Therapeutics (ATXS) has a market cap of $656M as of July 27, 2024.
What is the P/E ratio for Astria Therapeutics stock?
The price to earnings (P/E) ratio for Astria Therapeutics (ATXS) stock is 0 as of July 27, 2024.
Does Astria Therapeutics stock pay dividends?
No, Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Astria Therapeutics dividend payment date?
Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders.
What is the beta indicator for Astria Therapeutics?
Astria Therapeutics (ATXS) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Astria Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.